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EFFECT OF ROUX-EN-Y GASTRIC BYPASS SURGERY ON CONTROLLING 
TYPE 2 DIABETES MELLITUS 
HANNA KIM 
ABSTRACT 
Diabetes Mellitus is a form of metabolic disease with loss or dysfunction in 
glycemic control. Type II Diabetes Mellitus (T2DM) is characterized by the loss of 
glycemic control due to developed insulin resistance. T2DM is the most common form of 
diabetes and a growing epidemic that is affecting 9.4% Americans and 8.5% of the 
population worldwide. Associated with obesity, genetic predisposition, and 
environmental factors such as sedentary lifestyle, uncontrolled T2DM causes 
hyperglycemia, eventually leading to other potential complications including 
hyperlipidemia, increased risk for cardiovascular diseases, nerve damage and sleep 
apnea. Additionally, T2DM poses a high financial burden on the USA, costing $372 
billion in direct medical costs and reduced productivity. 
 Because obesity is the main driver of insulin insensitivity of T2DM, the current 
standard of care for T2DM focuses on managing the weight of patients. The initial 
approach of weight control entails lifestyle interventions, including exercise routine and 
diet change, with additional glycemic control medication prescribed if the first line of 
intervention is not effective. T2DM management is particularly challenging in obese 
patients, and many anti-hyperglycemic medications currently in the market lead to weight 
gain, which may further add to metabolic control problems. For such a challenge, 
bariatric surgeries are considered as a T2DM treatment option.  
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 Roux-en-Y gastric bypass (RYGB) is the most commonly practiced bariatric 
surgery in the United States. RYGB is shown to be the most effective treatment for 
prolonged weight loss leading to metabolic and hormonal changes that ultimately 
improve glucose metabolism and other complications of diabetes such as hypertension. 
Interestingly, these beneficial effects against T2DM are observed within days after the 
operation, before any significant weight loss takes place. T2DM patients after undergoing 
RYGB showed significant improvement in insulin sensitivity and increased insulin 
secretion. Additionally, up to 85% of patients showed complete T2DM remission through 
reporting significantly lowered fasting and post prandial blood glucose levels as well as 
lowered HbA1c value without the use of anti-hyperglycemic medication. In addition to 
T2DM remissions, T2DM-related complications were improved after RYGB. 
Improvement in hyperlipidemia, hypertension, and sleep apnea are reported after the 
operation.  
 The immediate, weight-loss independent anti-diabetic effects are resulting from 
the intestinal anatomic alteration from RYGB. This intestinal anatomical change leads to 
metabolic hormonal profile, bile acid metabolism, and gut microbiota composition.   
 Glucagon-like peptide-1 (GLP-1) is an incretin, or a hormonal factor secreted post 
prandially in the small intestine, that is known to promote insulin secretion and facilitate 
blood glucose level regulation. A significant increase in GLP-1 level is observed after 
RYGB. This change is hypothesized through hindgut theory and foregut theory.  
Protein Tyrosine Tyrosine (PYY) is another gut hormone secreted by L-cells in 
the ileum-colon. PYY was appreciated as an anorexigenic appetite regulator, and 
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recently, the hormone is recognized to play a direct role in glycemic control. Increased 
PYY serum level in patients after RYGB surgery is consistently reported, and this change 
in serum PYY explained through hindgut theory and foregut theory as PYY is co-
secreted with GLP-1. The increased level of PYY is shown to improve glycemic control 
in T2DM through the restoration of pancreatic islet morphology and function. 
RYGB not only affects the gut hormonal profile, but the operation also raises total 
circulating bile acid concentration. Bile acids have recently been appreciated as endocrine 
factors that stimulate the release of GLP-1 and PYY. Changes in gastrointestinal anatomy 
resulting from RYGB may affect enterohepatic recirculation of bile acid, leading to the 
observed increase in total bile acid. An increase in total bile acids is correlated with 
several markers indicating normalized glycemic control and changes in gut microbiota of 
the patients. 
The microbiota profile for T2DM patients is not fully established due to the 
inconsistent data reporting structures and discrepancies in reported results. Generally, 
decreased biodiversity in gut microbiota has been associated with increased obesity, and 
an increase in lipopolysaccharide-producing microbe drive the low-grade inflammation 
that leads to insulin resistance of the host. Reconfiguration of the gastrointestinal tract 
from RYGB leads to increased diversity in gut microbiota composition and markers 
showing improved metabolic state. Changes in gut microbiota after RYGB led to an 
increase in GLP-1 release through signaling pathways involving GPCRs activation and to 
increase in bile acids.  
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Roux-en-Y gastric bypass deems to be a safe, effective therapeutic option for 
T2DM treatment for obese to severely obese patients. The exact physiological 
mechanism of the effects of RYGB on T2DM patients still remains elusive, but the 
current understanding of the effects of RYGB had led to the discovery of many potential 
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Type II Diabetes Mellitus (T2DM) 
Type II diabetes mellitus (T2DM) is a growing epidemic that is affecting 9.4% 
Americans and 8.5% of the population worldwide. 1,2 Diabetes is a form of metabolic 
disease with loss or dysfunction in glycemic control. T2DM is characterized by the loss 
of glycemic control due to developed insulin resistance, or hyporesponsiveness to insulin. 
3 This uncontrolled glycemic control results in hyperglycemia in patients, especially 
postprandially, and T2DM can lead to other potential complications including 
hyperlipidemia, increased risk for cardiovascular diseases, nerve damage and sleep 
apnea.4 T2DM is the most common form of diabetes and is associated with obesity, 
genetic predisposition, and environmental factors such as sedentary lifestyle.  As obesity 
is the primary cause of T2DM, the prevalence of T2DM has been increasing with the 
obesity rate growing worldwide.5 Additionally, T2DM poses a high financial burden on 
the USA, costing $372 billion in direct medical costs and reduced productivity. 6 
The diagnosis of diabetes is established through the following criteria 
recommended by the American Diabetes Association. It is of note, that peptide-C test 
may distinguish Type I versus Type II diabetes by measuring the endogenous insulin 





Table 1. Prediabetes and Diabetes Diagnosis Criteria (Adopted from ADA 2019 
Report)7 
  Prediabetes   Diabetes 
A1C 5.7-6.4%*   ≥6.5% † 
FPG 100-125 mg/dL (5.6-6.9 mmol/L)*   ≥126mg/dL (7.0mmol/L) †  
OGTT 140-199 mg/dL (7.8-11.0 mmol/L)*   ≥200 mg/dL (11.1 mmol/L) † 
RPG     ≥200 mg/dL (11.1 mmol/L)‡  
 
A1C Measures average blood sugar for the past 2-3 months 
FPG Fasting Plasma Glucose 
OGTT Oral Glucose Tolerance Test 
RPG Random Plasma Glucose 
* For all three tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at the higher end of the range. 
†  In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate samples 
‡  Only diagnostic in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.  
 
Current Conventional Standard of Care for T2DM 
 Because obesity is the main driver of insulin insensitivity of T2DM, the current 
standard of care for T2DM focuses on managing weight of patients. It is well understood 
that obesity causes insulin resistance, with white adipose tissue playing a role as an 
endocrine organ, and systematic inflammatory state.8 The initial approach of weight 
control entails lifestyle interventions including exercise and diet change, with 
pharmaceutical or surgical interventions treated as the additional, secondary methods that 





 Studies show that exercise can help improve glycemic control with or without 
significant body weight loss. Exercise alone is proven to decrease Hb1Ac by 0.66%. 9 
American Diabetes Association (ADA) recommends adults with T2DM or 
prediabetes to engage in 150 minutes of exercise per week. The ADA guideline further 
outlines moderate or vigorous intensity aerobic activity should be done three days a 
week. For resistance exercise, 2-3 sessions per week is recommended, and the patient 
should interrupt prolonged sitting every 30 minutes. ADA also emphasizes on patient 
centered therapeutic guidelines, providing different exercise recommendation for 
different age groups. Children and adolescents are recommended to exercise 60 minutes 
or more a day. Moderate or vigorous intensity aerobic activity with vigorous muscle and 
bone strengthening activities should be done minimum 3 days a week. Elderly patients 
are recommended to engage in flexibility and balance training 2-3 times a week.7  
Obesity control has been proven to be beneficial in controlling T2DM. 10 
 
Pharmacologic Interventions 
Currently, the first line and preferred pharmacologic therapy is metformin to treat 
T2DM. Once metformin is initiated, it is recommended that the patient continue with the 
medication as long as the medication is well tolerated. Long-term use of metformin may 
cause biochemical vitamin B12 deficiency.  Based on the presence of co-morbidities and 
complications, additional agents can be introduced to the therapeutic routine. Several 
classes of medication for T2DM pharmacologic intervention are available in the market. 
	
4 
Each pharmaceutical agent entails health risks including potential weight gain, 
hypoglycemia, and detrimental cardiovascular and renal effects. (Tables 2-4) The 
American Diabetic Association recommends that patient-centered approach should be 
used when selecting pharmacologic intervention agent.  Thus, pharmaceutical 
intervention requires on-going monitoring of the patient’s status and flexible adaption of 
the plan according to the patient’s responsiveness to the prescribed medical plan (Figure 
1). It is to be noted that different population may have different health concerns that may 
not be reflected in the general guideline in Figure 1. For example, for pregnant women, 
for both Type I or Type II diabetes, insulin is the preferred pharmacologic intervention 
due to the fact that insulin does not cross the placenta. 7.  
Overall, the T2DM medication is expected to be taken over the course of lifetime, 
and often the blood glucose level may remain uncontrolled due to patients not adhering to 
the medication regime or not responding to the combination of medication.10  
Additionally, conventional pharmaceutical treatment of T2DM only partially achieves 
adequate glycemic control. T2DM management is particularly challenging in obese 
patients, and many anti-hyperglycemic medications currently in the market leads to 
weight gain, which may further add to metabolic control problems (Table 2). Many of 
current T2DM medication also do not reduce the cardiovascular or renal risks (Tables 3-
4). As a response to these challenges, bariatric surgeries have been considered for T2DM 





Table 2. Antihyperglycemic Treatments for Type 2 Diabetes and The Efficacy, Cost, 
and Risk of Hypoglycemia (Adopted from ADA Report 2019) 7 
 
		 		 Efficacy Hypoglycemia Cost 
Metformin   High No Low 
SGLT-2 Inhibitors   Intermediate No High 
GLP-1 Ras   High No High 
DPP-4 inhibitors   Intermediate No High 
Thiazolidinediones   High No Low 
Sulfonylureas (2nd 
Generation)   High Yes Low 
Insulin 
Human Insulin Highest Yes Low 
Analogs Highest  Yes  High 
 
Table 3. Antihyperglycemic Treatments for Type 2 Diabetes and The Risk of 
Cardiovascular Complications and Weight Change (Adopted from ADA Report 
2019)7 
		 		 CV effects Weight Change 
		 		 ASCVD CHF   
Metformin   Potential benefit Neutral 
Neutral (potential 
for modest loss) 
SGLT-2 Inhibitors   Benefit Benefit Loss 
GLP-1 Ras   Neutral/Benefit Neutral Loss 
DPP-4 inhibitors   Neutral Potential risk Neutral 




Generation)   Neutral Neutral Gain 
Insulin 
Human Insulin Neutral Neutral Gain 





Table 4. Antihyperglycemic Treatments for Type 2 Diabetes and The Risk of Renal 
Complications (Adopted from ADA Report 2019)7 
 
		 		 Renal Effects 
		 		
Progressions 
of DKD Dosing/Use Considerations 
Metformin   Neutral Contraindicated with eGFR<30 
SGLT-2 Inhibitors   Benefit Renal dose adjustment required 
GLP-1 Ras   Benefit 
Renal dos adjustment 
required for some. Caution 
when initiating or 
increasing dose due to 
potential risk of acute 
kidney injury 
DPP-4 inhibitors   Neutral 
Renal dose adjustment 
required in some. Can be 
used in renal impairment. 
Thiazolidinediones   Neutral 
No dose adjustment 
required. Generally not 
recommended in renal 
impairment due to potential 
for fluid retention 
Sulfonylureas (2nd 
Generation)   Neutral 
Initiate conservatively to 





Lower insulin doses 
required with a decrease in 
eGFR; Titrate per clinical 
response 






Figure I. Glucose-lowering Medications for Type 2 Diabetes: Overall Approach 




Bariatric surgeries, often referred as weight-loss surgeries, are procedures that 
cause weight loss through physical restriction on stomach capacity, causing 
malabsorption of nutrients, or combination of the both. The use of surgical procedures to 
treat obesity can be traced back to 1950s, but since then the practice of the procedures 
have grown more common due to increasing incident of obesity worldwide. 11 
Interestingly, additional clinical benefits outside of weight loss from these 
procedures have gained attention and have been reported. A recent meta-analysis has 
found that bariatric surgeries were “superior to conventional medical therapy in achieving 
significantly more weight loss, HbA1c and fasting plasma glucose (FPG) reduction, and 
diabetes remission.” 12 The study reported overall 63.5% T2DM remission rate in surgical 
intervention group compared to the 15.6% in the conventional group (p<0.001).  
The most commonly performed bariatric surgeries worldwide are laparoscopic 
adjustable gastric banding, sleeve gastrectomy, and Roux-en-Y gastric bypass.  
 
Laparoscopic Adjustable Gastric Band 
 Laparoscopic adjustable gastric banding (LAGB) operation involves placing a 
hallow, flexible silicone band around upper stomach just below the gastroesophageal 
junction (Figure 2). The method provides physical restriction on the stomach, reducing 
the stomach capacity. The operation results a very small gastric pouch above the band, 
providing the sense of satiety sooner due to the reduced capacity of the stomach. The 
operation is considered strictly “restrictive,” where the operation limits the total amount 
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of food intake without affecting the nutrition absorption capability of the digestive 
system.13 The level of restriction is adjustable in that the silicone band is tightened by 
injecting saline into the band through a subcutaneous port. 14 LAGB accounted for 24% 
of bariatric surgeries worldwide in 2003, and its prevalence rose to 42% in 2008. 
However, its popularity soon declined to 18% and eventually to 10%, in 2011 and 2013 
respectively, due to high complication rates and low weight loss and comorbidity 
resolutions. 11 
Post-surgical complications include band migration and adjustable port infection. 
The weight loss effectiveness and T2DM remission rate from LAGB is significantly low 




Figure 2. Adjustable Gastric Banding (Adopted from Neff et.al 2013)16 Adjustable 
gastric banding surgeries place a silicone, restrictive band below the junction of 
esophagus with upper stomach, creating a small gastric pouch above the band. The figure 





 Laparoscopic sleeve gastrectomy (SG) removes the entire fundus and majority of 
body of the stomach, leaving a narrow, tubular stomach referred as gastric “sleeve” after 
the resection (Figure 3). SG initially developed as an initial part of a two-step bariatric 
surgery, biliopancreatic diversion with duodenal switch (BPD/DS), a form of severe 
malabsorptive procedure. SG was proven to result good weight-loss and some remission 
of T2DM without the second step of BPD/DS, and currently is used as stand-alone 
bariatric surgery. SG is increasing in prevalence and popularity since the early 2000s for 
its effective weight-loss results and relative safety.11 Amongst the popular bariatric 





Figure 3. Sleeve Gastrectomy (Adopted from Neff et.al 2013) 16Sleeve gastrectomy, 
also known as vertical sleeve gastrectomy, removes 70-80% of the stomach, leaving a 
sleeve-like remainder of the organ. Because the excess stomach is completely removed, 






Roux-en-Y Gastric Bypass 
Roux-en-Y gastric bypass (RYGB) surgery is a procedure that involves creating 
anastomoses between the small gastric pouch near the esophagus and the distal loop of 
jejunum.  The nutrients, therefore, bypass the majority of the stomach, duodenum, and 
upper jejunum (Figure 4). RYGB surgery results in an alimentary limb, commonly 
referred as Roux limb, and a biliopancreatic limb where both limbs combined at the y-
intersection in ileum. The alimentary limb, or roux limb, include a small gastric pouch 
with anastomosed distal jejunum, and the biliopancreatic limb contains the bypassed 
portion of stomach along with bypassed duodenum that is connected with common bile 
duct and main pancreatic duct. 13 Currently, RYGB is considered as an obesity and T2DB 
intervention therapy option for the patients with BMI above 35.  
Bariatric surgery is considered the most effective intervention therapy to provide 
sustained normal glucose level for T2D patients, RYGB surgery being the most 
commonly performed procedure.17,18 RYGB is shown to be the most effective treatment 
for prolonged weight loss leading to metabolic and hormonal changes that ultimately 
improve glucose metabolism and other complications of diabetes such as hypertension. A 
large meta-analysis examining 621 studies has shown 80.3% of obese T2DM patients 
have experienced rapid and prolonged normalized plasma glucose level without any 
diabetes medication after RYGB. 19,20  
 RYBG facilitates sustained weight loss and therefore results in beneficial changes 
in glucose tolerance for T2DM patients. However, immediate improvements in glucose 
level after the procedure preceding substantial weight loss suggests a mechanism that is 
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independent of weight loss. 21 Additionally, RYBG has been shown to improve glycemic 
control in non-obese patients.22 The biological mechanism on how RYBG affects the 
glycemic control remains uncertain, but many studies have been exploring the 
involvement of changes in levels of intestinal hormones regulating hunger and insulin 
release and of changes in the composition of gut microbiota.  
 RYGB results in the greatest extent in sustained weight-loss and remission and 
improvements with T2DM, and hyperlipidemia when compared against other bariatric 
surgical techniques. 15 
 Key hormones involved in glucose metabolism include ghrelin and incretins – 
gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). 
Pathophysiology of T2D includes insulin resistance in hepatocytes and muscle cells, 
severely impaired GIP and GLP-1 secretion, abnormal glucagon secretion. As such, these 
hormones levels in T2DM patients with or without bariatric surgical intervention were 
studied as relevant endpoints when determining the remission state of diabetes, and it has 
been shown that GLP-1 secretion increases dramatically within a week of RYBG and the 
newly established level is sustained over a year. 21 More physiologic and metabolic 
markers outside of incretins should be studied to gain further insights on physiologic and 




Figure 4. Roux-en-Y Gastric Bypass (Adopted from Neff et.al 2013)16 Roux-en-Y 
gastric bypass surgery restricts stomach volume by generating a small pouch along the 
lesser curvature of the stomach to reroute nutrient flow from the upper stomach into the 
mid- to distal jejunum, thus bypassing most of the stomach, duodenum, and proximal 
jejunum. Roux-en-Y gastric bypass results in a biliopancreatic limb (green arrows) and 
an alimentary limb, or also referred as Roux limb (red arrows), and both limbs join at the 
y-intersection in ileum. The route of travel for food bolus is indicated in red arrows from 




 Gut microbiota is a complex ecosystem of the microbes inhabiting inside the 
human gastrointestinal tract.  This ecosystem of trillions of microbes not only include 
bacteria but also protozoans, archaea and viruses. 23 Gut microbiota interacts with a host 
via “1) modulating the inflammatory host response to the gut, 2) synthesizing small 
molecules and proteins that are taken up by the host, and 3) changing the amount of 
available energy in the diet.” 24  Intestinal microbial colonization ranges from 102 colony-
forming units (CFU)/g in the proximal gut. The number of microbial colonization and 
diversity increase in the distal gut to 1012 CFU/g. 25 Therefore, changes in intestinal 
anatomy through surgical procedures such as RYGB may affect the microbiota 
composition and diversity. In rodent, gut microbiota transplant showed changes in 
metabolic and physical phenotypes, showing potential involvement of microbiota 
composition in metabolic diseased states. Several studies have shown that transferring gut 
microbe samples from obese mice into germ-free mice increased adiposity in the microbe 
recipients. 3,26 In reverse, a small report has shown that transfer of gut microbiota sample 
from lean mice into obese, diabetic mice has increased the insulin sensitivity. 27 Hence 
the composition or changes within the gut microbiota population provides an area of 
study to explore the potential biological mechanism behind the immediate beneficial 






The main objectives of this thesis are to discuss the benefits of Roux-en-Y gastric 
bypass surgery as a treatment for Type II Diabetes Mellitus and to understand potential 
physiologic mechanisms currently proposed in the field that explain the beneficial health 
outcomes from Roux-en-Y gastric bypass surgery for Type II Diabetic patients via a 
literature review. 
 
The objectives will be met via below specific aims.  
This thesis aims to: 
1. Report the current observation of the weight-loss independent clinically beneficial 
effect of Roux-en-Y gastric bypass; 
2. Report the metabolic profile changes from Rou-en-Y gastric bypass surgery; 
3. Identify the current understanding of the correlation between Roux-en-Y gastric 
bypass surgery and intestinal hormone secretion;   
4. Report the current understanding of changes in bile metabolism resulting from 
Roux-en-Y gastric bypass surgery, and; 
5. Identify the current understanding of patterns in the gut microbiota of Type II 
Diabetes Mellitus patients and that of those who have received the Roux-en-Y 





PUBLISHED STUDIES  
 
Clinical Outcomes of Roux en Y Gastric Bypass and Observed Changes in 
Metabolic State 
 A substantial body of studies have now proven that bariatric surgeries lead to 
superior glycemic control and reduction of other co-morbidities of T2DM and obesity - 
including cardiovascular diseases - compared to lifestyle change and pharmacologic 
intervention alone. 7,28 Amongst the bariatric surgeries, RYGB show the most significant 
improvements in sustained weight loss and glycemic control with the lowest 
complication rate. 12,20  
In a large meta-analysis study in 2004 showed that RYGB proved to be an 
effective surgical therapy for obesity by reducing weight and BMI of the patients, but 
also improved comorbidities associated with obesity. RYGB resulted in resolution and 
improvement on type 2 diabetic state, hyperlipidemia, hypertension and obstructive sleep 
apnea.22 Interestingly, such improvements in comorbidities of obesity was not observed, 
or was observed in lesser degree, in strictly restrictive surgical methods such as gastric 
banding or gastric sleeve surgeries. 29  
Several studies have reported that patients undergoing RYGB show rapid insulin 
resistance resolution and increased insulin secretion, even before the significant weight 
loss.30 Additionally, in 3 months post-surgery, decrease in BMI, fasting p-glucose, and 
Hb1Ac was observed, and these markers stayed lower than baseline after a year, proving 
a sustained positive effect. 31 Further, remission of diabetes mellitus occurs in 60% to 
80% of patients 1 to 2 years after RYGB surgery, and remission is retained in 
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approximately 30% of patients at 15 years. 14 These observations are consistent with the 
results from a longitudinal study with a Denmark cohort by Jorgenen et al.  T2DM 
patients who received RYGB showed significantly improved glycemic control measured 
by decreased HbA1c, fasting glucose and peak glucose. Additionally, the study reports 
significantly reduced postprandial nadir glucose in T2DM patients after RYGB, 
indicating improved insulin response. All measurements showed significance at p<0.001 
when compared to pre-operational baseline measurements. These improvements were 
sustained in repeat measurements in 1-year post-operation and >2 year post-operation 
marks. Significantly increased insulin secretion was observed through both peak insulin 
level. Fasting insulin level as well as fasting C-peptide level were decreased significantly 
(p<0.001, when compared to pre-operation state), indicating normalized insulin 
regulation. Interestingly, decreased glucose level, both fasting and post-prandial states, 
and increased in insulin secretion were observed after RYGB in non-T2DM patients as 
well. 32  
RYGB provides more frequent diabetes remission with significantly fewer 
complications from diabetes mellitus when compared to non-surgical T2DM treatments. 
A long-term follow up observation study in Sweden has shown that a cohort of obese 
T2DM patients who have received RYGB had microvascular complications incidence 
rate of 20.6 (95% CI, 17.0-24.9) per 1000 person-years compared to the non-surgical 
control group’s 41.8 (95% CI, 35.3-49.5) per 1000 person-years. Hazard ratio (HR) of 
microvascular complications in RYGB group compared to the control group is 0.44 (95% 
CI, 0.34-0.56; P<0.001). RYGB is also shown to significantly reduce the incidence rate 
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of macrovascular complications with 31.7 (95% CI, 27.0-37.2) per 100 person-years from 
the incidence rate of the non-surgical group of 44.2 (95% CI, 37.5-52.1). The reported 
HR 0.68 (95% CI 0.54-0.85; p=0.001) show that patients who have received RYGB is 
0.68 times likely to develop diabetes related macrovascular complications compared to 
those who received standard non-surgical treatments. 12 
 Outside the outcomes measured by clinically relevant markers, many studies have 
shown distinct metabolite profiles in patients and mice after RYGB compared to the 
sham-operated controls and those who have lost the similar weight through strictly diet 
change. In a mice model, RYGB upregulated genes involved in citric acid cycle, β-
oxidation, mitochondrial electron transport chain, and fatty acid synthesis in 
subcutaneous inguinal white adipose tissue. Same pattern was observed in human data. 33 
In several rodent models, consistent pattern of urinary metabolite profile suggested 
enhanced tricarboxylic acid cycle activity after RYGB surgery. Urinary levels of citrate, 
fumarate, 2-oxoglutarate and succinate decreased post RYGB surgery, indicating an 
increase TCA activity.34 Additionally, RYGB reduced plasma lipids and increased 
pyruvate, lactate and alanine, suggesting increased lipid metabolism and glycolysis. 
Elevations in the concentrations of hepatic glycogen, glucose, glycerol, lactate and 
alanine suggested the downregulation of gluconeogenesis and an increased conversion 
between glycogen and glucose. 34  
The exact mechanism of how RYGB induce improved glycemic control is still 
controversial and heavily studied. Currently, the field theorizes that the beneficial effect 
of RYGB involves the alteration in the gastrointestinal anatomy and therefore promoting 
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the secretion level of metabolically active peptides such as GLP-1 and PYY. Others 
suspect that change of anatomy may affect the composition of gut microbiota, involving 
resolution of systematic inflammation that leads to improved glucose metabolism. 
Gut Hormonal Changes  
GLP-1 and Insulin Secretion 
 Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 
(GLP-1) are often referred as incretins, or hormonal factors secreted post prandially in the 
small intestine that are known to promote insulin secretion and facilitate blood glucose 
level regulation. GIP is secreted from the K-cells in proximal portion of the small 
intestine, in duodenum, primarily in response to fat or glucose ingestion. GIP, however, 
was shown that it alone cannot account for the increase in insulin release after food 
ingestion. Additionally, GIP was proven to play a minor role in regulation for insulin 
secretion, and GLP-1 was deemed as the main humoral factor associated with blood 
glucose regulation through insulin secretion facilitation. 35 GLP-1 has gained much 
attention to be the key player involved in the weight-loss independent mechanisms of 
T2DM remission, or improvements in glucose-induced insulin sensitivity, from RYGB 
surgeries.  
 GLP-1 is secreted by intestinal L-cells in response to nutrient ingestion. GLP-1 
plays a major role in physiological response to glucose intake in multiple organs (Figure 
5). GLP-1 facilitates these responses though increasing insulin secretion and enhance 
insulin biosynthesis through promoting pancreatic b-cell proliferation and decreasing b-
cell apoptosis. Ultimately, regulation on glucagon secretion and enhanced insulin 
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secretion lead to increased insulin sensitivity which results in cascades of improved 
metabolic responses in various organs including liver, adipose tissue, skeletal muscle, 
heart, and brain. In addition to its effect on pancreas and pancreatic hormones, GLP-1 
improved blood glucose concentration regulation through decreased hepatic glucose 
production and increase glucose uptake and storage by the skeletal muscle. This 
involvement of GLP-1 with multiple organ system in regard to glucose-induced insulin 





Figure 5. Roles of GLP-1 In Different Organs (Adopted from Baggio et al 2007)35 
 
Studies have established that T2DM patients show significantly lower serum 
GLP-1 level compared to healthy controls.36 The serum GLP-1 level, however, was 
significantly elevated in diabetic patients who underwent RYGB surgery compared to 
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their baseline level prior to the operation. Similar effect is observed in a study where 
high-fat diet fed Sprague Dawley rat that underwent RYGB operation showed 
significantly elevated GLP-1 serum level compared to the group that received the sham 
operation. Circulating level of GLP-1 of RYGB received rats on 53-day post-operation 
was 71.5 ± 11.7 𝑝𝑚𝑜𝑙!", significantly (p = 0.001) higher than the GLP-1 level of the 
sham operated rats of 10.5 ± 3.3 𝑝𝑚𝑜𝑙!". 34 
 The significant increase in serum GLP-1 level has been observed after the gastric 
bypass surgery, in both humans and rodent T2DM models, which leads to metabolic 
improvement such as increased insulin secretion. 37-41 Of note, fasting GLP-1 level did 
not show any significant difference between the control patients and RYGB patients, but 
post prandial GLP-1 level was increased significantly in RYGB patients. 42. Ultimately, 
the metabolic improvement from increased GLP-1 secretion is widely understood to be a 
main factor independent from the weight loss or caloric restriction that leads to T2DM 
remission.36 
 It is of interest to note that RYGB operation itself is what stimulates the GLP-1 
release and its effect, not necessarily the weight loss. Obese patients with T2DM saw 
significant increase in stimulated GLP-1 level by a factor of six (peak GLP-1: 17±6 to 
112±54 pmol/liter, p<0.001) after RYGB surgery. When the control group of obese 
patients with T2DM achieved similar weight loss as the surgical patients through diet 
only, their GLP-1 levels tended to decrease compared to their baseline. 28. A significant 
linear relationship was observed between total GLP-1 release and insulin release only in 
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RYGB surgery group compared to the control diet induced weigh tloss group during the 
oral glucose tolerance test (OGTT) (r = 0.762; p = 0.028).  
Not only did RYGB operation increase the absolute post prandial serum levels of 
GLP-1, but the surgery also improves the attenuated incretin effect in T2DM. In healthy 
individuals, insulin production, promoted by GLP-1 release, is greatly stimulated when 
glucose is administered through oral ingestion. Meanwhile, intravenous administration of 
glucose does not result in substantial insulin production leading to observable blood 
glucose level regulation. Such administration route-specific stimulation of insulin release 
is termed the incretin effect. (Figure 6A) Incretin effect confirms the importance of role 
of intestinal cells and the factors released from the intestines in insulin secretion 
regulation. In T2DM patients, the incretin effect is diminished (Figure 6B.) Laferrer et al. 
showed that insulin response was not significantly different between oral and intravenous 
glucose administration in T2DM patient prior to weight loss interventions. After RYGB 
surgery, the patients showed significantly increased incretin effect by a factor of 3.8 
(+35.4 ± 22,7%, p=0.009). Patients who experienced similar weight loss as RYGB 
surgery patients through diet did not show significant improvement in incretin effects 





Figure 6. Incretin Effect in A.) Healthy Patients and B.) Type 2 Diabetic Patients 
(Adopted from Nauck et al. 1986) 43 A markable decrease in incretin effect (dashed 
double arrow) is observed in Type 2 Diabetic patients when compared to healthy patients.  
 
The exact mechanism of RYGB operation leading the increased GLP-1 secretion 
still remains elusive, but there are two proposed mechanisms on how RYGB may affect 
the GLP-1 secretion through alteration of gastroenteric tract anatomy.  
 The Hindgut Hypothesis suggests that gastroenteric anastomosis resulting from 
RYGB leads to an early stimulation of L-cells by undigested nutrient leads to increased 
secretion of the incretins. 27 GLP-1 staining cell density was found higher in distal 
portion of the small intestine, 200 cm and onwards after the duodenal angle. After the 
RYGB operation, intestinal anastomosis will introduce undigested food to distal portion 
of the small intestine due to shorter travel of the food from esophagus to jejunum, 
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exposing L-cells with non-digested nutrients. Interestingly, a study has shown that the 
extent of anti-diabetic effects vary depending on the length of the biliopancreatic limb 
resulting from the RYGB surgery. Longer biliopancreatic limb was shown to result in 
greater extent of weight loss and better metabolic state than operations with shorter 
biliopancreatic limb. 44,45.  
 The Foregut Theory suggests that the nutrient introduction to the proximal portion 
of small intestine leads to the secretion of potential anti-incretin factors. Bariatric 
surgeries that rearrange the gastroenteric anatomy avoids duodenum to jejunum to food 
material, which in turn results in balanced secretion of the incretins and anti-incretin 
factors, ultimately improving glucose metabolism. GIP secreting K cells densely 
populated in duodenum and proximal jejunum, and GIP analogues stimulate glucagon 
secretion while does not affect insulin secretion or affect glucose metabolism. 27,44.   
 As GLP-1 was heavily studied as the main humoral factor that mediates insulin 
secretion, GLP-1 was regarded as the potential therapeutic target for T2DM. Currently, 
GLP-1 receptor agonists still remain one of the commonly used pharmacologic 
intervention agents for T2DM. 
 
Protein-Tyrosine-Tyrosine (PYY) and Pancreatic Islet Function and Morphology 
For over two decades, the beneficial glycemic control effect of RYGB 
independent of weight loss and caloric restriction was thought to be explained through 
the involvement of GLP-1. As demonstrated in the earlier section, increased level of the 
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incretin hormone GLP-1 was thought to be the triggering and responsible factor for the 
improved glucose homeostasis and T2DM remission after the RYGB.  
 However, recent studies in pancreatic islet functions after RYGB have shown that 
GLP-1 does not have effect in restoring damaged pancreatic islets in T2DM patients.46 
GLP-1 receptor knockout T2DM rodent model also demonstrated improved glucose 
metabolism after RYGB operations. 47 These findings suggest that GLP-1 may not be the 
key factor that mediates the immediate and sustained benefits of RYGB, and that GLP-1 
and its receptor may not be appropriate targets for pharmaceutical therapies.  
 Protein Tyrosine Tyrosin (PYY) is another gut hormone secreted by L-cells in the 
ileum-colon. Similar to GLP-2, PYY is secreted in response to glucose intake. Prior to 
mid-2010s, the established role of PYY in metabolism was an anorexigenic appetite 
regulator. Increased PYY serum level after RYGB surgery was observed by several 
studies, with the speculation that the role of PYY in improvement of patients who 
underwent RYGB is through suppressing their appetite, and thus decreasing their food 
intake and promoting weight loss that leads to overall metabolic improvements of the 
patients.48  
Since the discovery of the fact PYY production is not exclusively done in the 
intestine - but also in the pancreatic islet cells – PYY’s potential paracrine role in 
pancreatic islet function, specifically glucose metabolism, has been speculated.  
 Human T2DM patients’ pancreatic islet show both morphological and functional 
damage. Dysfunction in glucose stimulated insulin secretion from pancreatic β-cells and 
in glucagon secretion regulation from pancreatic alpha cells define T2DM pathology. 49 
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The overall mass of the pancreatic islets is smaller in T2DM compared to those of the 
BMI and age matched healthy individuals. Diabetic patients’ pancreatic islets presented 
decreased proportion of insulin producing β-cells while that of the glucagon producing 
alpha cells were increased when compared to non-diabetic individuals’ pancreas. The 
small islets from T2DM patients also often presented a donut-like shape with a central 
pale region identified with dithizone staining that was not observed in healthy subjects’ 
pancreatic islets. 50 Additionally, the healthy rodent subjects’ pancreatic isles sections 
possess spheroid shapes under histologic assessment while diabetic rodents show 
distinctive islet outline that is described as “star-shaped”. 51 
 Interestingly, pancreatic islet morphology of both diabetic patients and rodents is 
improved after RYGB.46,47 In diabetic rat model, Goto-Kakizaki (GK) rats, subjects that 
went under RYGB has pancreatic islets with increased overall mass and increased 
insulin-active regions when compared to the diabetic rats that have gone through a sham 
operation. These changes in islet morphology between the RYGB group and sham 
operation group was significant with p-value <0.005. The GK rats who undergo RYGB 
surgery show spheroid pancreatic islets, which are significantly different from the star-
shaped islets of sham operated GK rats. 47 These results show the reversibility of the 
pancreatic islet morphological damage through RYGB alone.  
 Not only morphology, the islet function improves significantly after RYGB in 
glucose-induced insulin secretion as well as glucagon secretion regulation when 
compared with sham operation.  
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 The islet morphology and function corrections from RYGB are ultimately 
correlated clinical improvements of T2DM. Insulin release in response to an oral glucose 
load is delayed in T2DM because of pancreatic β-cell dysfunction, which results in 
elevated postprandial blood glucose concentration. 52 The GK rats with RYGB operation 
showed significant increase in insulin secretion (13.1ng/islet in RYGB group compared 
to 6.9ng/islet in sham operated controls), significant decrease in blood glucose levels, 
greater extent of weight loss (8% body weight in RYGB group versus 1% body weight in 
sham operation group) and decreased water intake by 4-folds. 47 These metabolic 
improvements indicated T2DM remission through RYGB. 
 Increased serum PYY level was observed in both human patients and rodents after 
RYGB through several studies. Guida et al. have shown when compared to the control 
diabetic patients, those who has undergone RYGB showed increased serum PYY by 25% 
at 6-month post-surgery follow up. 46 In GK diabetes rodent model, a significantly higher 
level of PYY was recorded after RYGB compared to the subjects with sham operation. 47 
Given that PYY is co-secreted with GLP-1 from L-cells, the increased PYY level after 
RYGB could be explained through the foregut theory as well. Recent studies offer 
alternative mechanisms on how PYY level could increase after bariatric surgeries. Guida 
et al. demonstrated that propionate and bile acids mimic the effects of RYGB by inducing 
pancreatic PYY release and potentiating insulin secretion. Additionally, the group also 
showed IL-22 modulate PYY expression and release from enteroendocrine cells and 
pancreatic islets. 46 Alteration in bile acid level and composition from bariatric surgeries 
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has been reported in the past, and the changes in gut microbiota profile may lead to 
increased propionate and IL-22 expression.46,53 
 Ramracheya et al. demonstrated that PYY is the key effector that drives the early 
recovery of the impaired glucose-induced insulin secretion and glucagon secretion after 
RYGB, and the recovery is achieved through the pancreatic islet morphology and 
function recovery. Isolated rat pancreas islets were treated with sera of rats underwent 
RYGB and sera of the sham operated rats. RYGB rat’s sera induced significantly 
increased insulin secretion from pancreatic islets when exposed to higher concentrations 
of glucose. Additionally, RYGB rat’s sera also significantly suppressed glucagon 
secretion in response to raised glucose level. This study successfully demonstrated that 
improved insulin and glucagon secretion and regulation is not due to physical weight loss 
and inflammation state, but from humoral factors that is affected by RYGB surgery. 47 
 Specifically, PYY is identified as the humoral factor that promoted cellular 
proliferation of pancreatic islet and improved the β-cell function. 47 
 PYY infused diabetic rats showed decrease in body weight and Hb1Ac levels, 
establishing the causal relationship between the PYY level and the improved glucose 
metabolism. 54 With similar mechanisms, PYY was identified to be play the critical role 
in T2DM resolution in humans as well. 46 
 Interestingly, PYY is also found “centrally in neurons in the gigantocellular 
reticular nucleus of the hindbrain from which they project to the dorsal vagal complex 
and the hypoglossal nucleus”. This presence of PYY in the specific regions of central 




Changes in Bile Acid Metabolism after Roux en Y 
  Bile acids (BAs) have long been recognized as amphipathic surfactants 
that promote intestinal absorption of dietary lipid and fat-soluble vitamins. The primacy 
bile acids – cholic acid and chenodexycholic acid– are synthesized in the liver from 
cholesterol, and subsequently conjugated to glycine or taurine to produce bile salts. 
Thereafter, the bile salts are deconjugated in the colon by the intestinal bacteria to 
produce secondary bile acids - deoxycholic acid and lithocholic acid.25,56 Bile acids are 
efficiently reabsorbed in the ileum (>95%) and reabsorbed and recycled back to the liver 
for further re-secretion. This recycling process is called enterohepatic circulation. 25 
Outside of its role in lipid absorption, bile acids composition and level have been 
appreciated recently as a factor playing a role in regulating metabolism.  
In recent studies, bile acids are identified as endocrine factors that stimulate 
release of GLP-1 and PYY. 57-59 Additionally, bile acids are important modulator of 
whole-body metabolism that aid in increased energy expenditure, preventing obesity, 
insulin resistance, and hyperglycemia in a rodent model.53 Bile acids are synthesized in 
the liver from cholesterol, so they are involved in cholesterol homeostasis as well. These 
findings now deem bile acids as the important endocrine factors that regulate glucose and 
lipid metabolism.  
Changes in gastrointestinal anatomy resulting from RYGB may affect 




 In diabetic rats that received RYGB surgery, total serum bile acid was 
significantly higher than the sham operated control groups post-prandially. Increased 
serum bile acid also correlated with increased GLP-1 and PYY concentrations, along 
with improved glucose-induced insulin sensitivity in RYGB operated rats. 60. In human 
patients, circulating bile acid level was significantly correlated with measured insulin 
sensitivity. When compared to weight-matched overweight control subjects, obese 
patients who received RYGB surgery showed 2.5-fold increase in total bile acid 
(p<0.001). When compared to pre-surgery weight-matched severely obese control group, 
post-RYGB patients showed 2.3-fold increase in total bile acid (p = 0.045)  53 In another 
study, a significant increase in total bile acid was observed in obese T2DM patients 1 
month post-RYGB surgery due to increase in secondary bile acids. The increase in 
secondary bile acid was correlated with observed hepatic insulin sensitivity. Further, the 
patients saw increase in both primary and secondary bile acids 24 months post-operation, 
and the long-term increase is suggested to be bacterially derived. 61 
 Increase in total bile acids showed correlation with several markers indicating 
normalized glycemic control. Total bile acids were positively correlated with plasma 
adiponectin, a marker of insulin sensitivity (r = 0.48, p <0.002) in obese T2DM patients 
who underwent RYGB. Total bile acid concentration also showed strong inverse 
correlation with 2-h post-meal blood glucose level (r=-0.59, p<0.003) while showing 
patterns of negative correlation with fasting glucose concentration (r = 0.40, p < 0.06) 
and with hemoglobin A1c (r = -0.38, p = 0.07). It is of note that serum bile acid levels did 
not correlate with BMI in either surgical cohort or the non-surgical control group. 53 The 
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lack of correlation between bile acid level and BMI suggest that the metabolic and bile 
acid circulation changes observed after RYGB may be weight loss independent. 
Additionally, weight-loss from a hypocaloric diet did not increase the bile acid 
circulation, but instead decrease the amount of unconjugated bile acids, further indicating 
that the relationship between anti-diabetic effects and bile acid level alteration after 
RYGB is distinct from other metabolic mechanisms involving weight-loss of patients.   
 Primary and secondary bile acids are signaling molecules acting on a family of 
nuclear and G-protein coupled receptors that are involved in modulation of insulin 
signaling, energy expenditure, and alleviation of liver lipid accumulation. 25 Bile acids 
binds to farsinoid X receptor (FRX), a nuclear hormone receptor in the intestines. FXR 
activation leads to fibroblast growth factor 15/19 (FGF 1/19), which maintain normal 
levels of lipids (normo-lipidemia) and glucose (normo-glycemia). Activation of FXR is 
also involved with downstream decreased hepatic glucose production.57 FXR activation 
of L-cells in ileum by bile acid may be a part of the mechanism of T2DM resolution after 
RYGB.  
 Improved insulin resistance and diabetic control may partly be due to alteration of 
bile acid composition and the subsequent stimulation of GLP-1 secretion.  Bile acids 
increased GLP-1 production through a bile acid receptor, G-protein coupled bile acid 
receptor 1 (Gp-BAR1) in murine enteroendocrine cell line. 57 
  Some literatures also indicate the changes in gut microbiota profile from obesity 
and T2DM may disrupt the conjugation of primary bile acids into the secondary bile acid, 
which may downregulate the FXR.25 
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Microbiota Changes after Roux en Y 
 The notion of gut microbiota composition associated the metabolic phenotype has 
been speculated since it is well accepted that gut microbiota contributes to the energy 
balance of the host. 3. Significant changes in composition of gut microbiota was observed 
between T2DM group compared to the normal cohorts in both rodent models as well as 
in humans. 62 Further, such changes in intestinal bacterial population in T2DM were 
observed in several studies across varying populations. 3  
 Current hypothesis on how gut microbiota dictates the metabolic phenotype, such 
as insulin resistance, is that the increase of microbes producing lipopolysaccharides 
(LPS) drive the low-grade inflammation with their bacterial products, which eventually 
leads to insulin resistance and T2DM (Figure 7). Increased adiposity is also associated 
with low-grade inflammation that may lead to insulin resistance. Increased level of pro-
inflammatory cytokines is observed in obese mice and human subjects, released from 
adipose tissues themselves and recruited macrophages. 3 Alternatively, Cani et al., 
suggests that the low-grade inflammation is promoted when the gut microbiota products, 
such as LPS, enters the portal circulation via “leaky” gut mucosa and eventually activates 




Figure 7. Overview of Microbiota Dysbiosis Resulting Type 2 Diabetes (Adopted 
from Adeshirlarijaney 2020)3 
 
The microbiota “profile” for T2DM patients is not fully established due the 
discrepancies in reported results at microbe species level. This discrepancies in results 
may be due to differences in analysis, diet, and genetic and environmental components. 
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Inconsistent reporting style in the published literature pose an additional challenge in 
establishing a consensual microbiota profile for specific metabolic states. However, 
several patterns are observed at the genus level. Genera Bacteroides and Bifidobacterium 
are commonly reported in the literature as negatively associated with T2DM. Genera 
Faecalibacterium, Akkermansia, and Roseburia are less commonly reported but are 
consistently negatively associated with T2DM. For example, Akkermansia muciniphila 
was decreased in diabetic rodent model, and when re-introduced to the subjects, 
antidiabetic effects were observed. 64 In contrast, genera Ruminococcus, Fusobacterium, 
and Blautia are reported to be positively associated with T2DM. 65 Lactobacillus, 
although commonly studied, showed discrepancies in its association with T2DM. 65 
Others have also reported the characteristics of microbes by their metabolic 
byproducts instead of reporting the genus. Roseburia intestinalis and Faecalibacterium 
prausnitizii, bacteria identified to be butyrate-producing, showed lower concentrations in 
T2DM patients when compared to healthy cohorts. Many studies have shown that in 
rodent model, lean subjects had gut microbiota that produced more short chain fatty acids 
(SCFAs), especially butyrate and propionate. These SCFAs were shown to act as 
signaling molecules activating G-protein coupled receptors and inhibited fat 
accumulation and increased energy expenditure, ultimately increasing better insulin and 
glucose tolerance.66  The overall trend in gut microbiota population involved in different 
metabolic process is visualized in Figure 8. 




 An exact mechanism of how different gut microbiota composition results in the 




Figure 8. Literature-based network analysis of potential effects on metabolism of 




 With the understanding that the gut microbiota may be a determinant of metabolic 
disease state, it is natural to study changes in the composition of gut microbiota take 
place after RYGB.  
 Palleja et al. has shown that RYGP leads to increased diversity in gut microbiota 
composition and markers showing improved metabolic state. Most of the microbiota 
changes were shown to start within 3 months post-surgery, and these effects were 
sustained over a year. The microbiota composition did not show significant difference 
when compared to the microbiota profile 1 year. In this study, obese patients with and 
without T2DM were followed longitudinally from baseline through post RYGB.31  
Interestingly, some conserved changes in microbiota composition was observed 
across species – rat, mice and human – after RYGB when compared to the control, sham 
operation group. A decrease in Firmicutes and increase in Bacteroides and 
Proteobacteria were observed in the gut microbiota of patients who received RYGB. 
This trend was associated with weight loss.24 Given that the changes in gut microbiota 
profile has changed shortly after the surgery, the results suggest the beneficial effect of 
RYGB on weight loss and T2DM remission was from reconfiguration of the 
gastrointestinal tract, not the above-mentioned potential cofounding factors. 62 
 It is notable that the relationship between GLP-1 secretion and gut microbiota has 
been observed. SCFAs produced in the colon from fermentation of dietary fibers bind to 
G-protein couple receptors (GPCRs) known to trigger GLP-1 secretion - GPR41 and 
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GPR43. Akkermansia muciniphila is known to regulate other compounds identified as 
ligands of other GPCRs leading to GLP-1 secretion by the L-cells.67 In a 2006 study, 
when healthy subjects were given oligofructose for 2 weeks to alter the gut microbiota 
profile, increased GLP-1 and PYY levels were observed.68 
Just as the gut microbiota influences the gastrointestinal hormones, gut microbiota 
is intimately related to the bile acid metabolism. It was widely understood that intestinal 
bacteria play a major role in deconjugation of bile salts in the intestines. Reciprocally, 
bile acid composition and level seem to affect the gut microbiota profile. Bile acids play a 
antimicrobial role in shaping the gut microbiota profile. Decreased bile acid level in the 
intestines favor gram-negative bacteria in microbiome, some of which produce LPSs and 







Roux-en-Y gatric bypass is proven to lead to superior results in blood glycemic 
control and T2DM remission rates compared to conventional therapies including lifestyle 
changes and hypoglycemic medications. Even amongst bariatric operations, RYGB show 
the greatest extent of beneficial effects in sustained glycemic controls and weight-loss. 
However, when considering RYGB as a standard treatment for T2DM, a few factors need 
to be addressed.  
The American Diabetes Association states that the individuals with diabetes 
should assume an active role in their care. Not only should the patients be part of care 
plan design, but they should also be adhering to the plan. 7 Such recommendation is 
based on observed reverted beneficial effects in patients who received surgical 
interventions. One of the prominent studies that highlighted the possible relapse of 
T2DM is the Swedish Obese Subject (SOS) study that followed obese T2DM patients, a 
cohort who received RYGB and a control cohort who only receive lifestyle changes and 
pharmaceutical interventions, over 15-year period. This Scandinavian long-term follow-
up observational study demonstrated that T2DM remission was observed in 72.3% of 
surgical group after 2 years of RYGB, but the proportion dropped to 38.1% and 30.4% in 
10 year and 15-year post-operation time points, respectively. These proportions were still 
remained higher than the control group that did not receive RYGB. 12 Although RYGB 
may still be more effective treatment for T2DM than lifestyle changes alone and/or 
pharmaceutical intervention, the overall effectiveness drops over time, suggesting 
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potential weight regain and dysregulated glycemic control post-operation.  This relapse 
into T2DM status after remission may be caused by the patients’ negligence or 
incompliance to the recommended diet and exercise guidelines post-operation. When 
considering RYGB as a surgical treatment for T2DM, patient education would be crucial 
to help the patient understand that surgery alone will not be an easy, one-step permanent 
cure for the disease.  
Considering Roux-en-Y gastric bypass as a surgical treatment for T2DM also 
entails risks of inherent surgical complications including the blind loop syndrome. RYGB 
operation involves gastrointestinal anastomosis, creating a loop that ingested food 
bypasses during digestion. This “blind loop” causes food and waste products to travel 
through newly routed digestive tract, often at a slower pace, causing bacterial overgrowth 
in the small intestine. Such bacterial overgrowth may cause abdominal pain, diarrhea, and 
malnutrition. The blind loop syndrome may lead to more health complications including 
vitamin B-12 deficiency, damage to the intestinal lining, and osteoporosis.70 Given the 
extremely invasive nature of the operation, patients need to meet stringent criteria to be 
eligible for the surgery. The surgery will not be a feasible therapeutic option for T2DM 
only without underlying severe obesity because of the possible surgical complications 
and risks along with permanent micronutrient malabsorption.  
Despite the promising positive clinical outcomes for the obese T2DM patients, 
prescribing a major operation such as RYGB to all the T2DM patients would be 
unnecessarily risky and impractical. Studying the physiological and molecular 
mechanisms involved in the beneficial effects of RYGB surgery has been of high interest 
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to identify potential therapeutic targets to obtain such anti-diabetic results without the 
surgery. Although both physiological and molecular mechanisms involved in RYGB 
operation’s positive clinical outcomes have been heavily studied, discrepancies in 
reported results exist, leaving the exact mechanism of how RYGB lead to T2DM 
remission remain still elusive.  
An appreciation of bile acid as one of the main mediators that plays a role in 
immediate anti-diabetic response after RYGB surgery has been challenged. A prospective 
observational study by Jorgensen has concluded that acute improvements in glucose 
metabolism after RYGB is not explained by increase in total bile acid. In the study, 
normal glucose tolerant patients who underwent RYGB showed decrease in both fasting 
and postprandial state total bile acid 7 days post-operation. T2DM patients did not show 
any change in their total bile acid level within the same time frame after the surgery. Both 
groups showed increase in bile acid at 3-month and 1-year post-surgery time points. The 
delay in changes in total bile acid does not parallel the timeline of the immediate anti-
diabetic effects observed after RYBG surgeries within mere days. The study also did not 
find any significant changes in bile acid composition before and after the surgery. 21 The 
inconsistency in the data presented by the work of Jorgensen et al., and other body of 
studies that argue the central role of bile acid in improved glucose metabolism might be 
explained by the fact that the fat content of the patients’ diet has not been controlled.  
The hindgut theory that explains the increase in GLP-1 and PYY secretion after 
RYGB surgeries is also questioned with inconsistent results regards to different 
techniques used in the surgery. Earlier, it was mentioned that studies have shown that 
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longer biliopancreatic limb leads to better clinical outcomes after the RYGB procedure, 
indicating that introducing undigested nutrients to lower small intestinal region with high 
L-cell density leads to high levels of GLP-1 and PYY. However, a small number of 
studies have concluded that length of biliopancreatic limb does not lead to any significant 
improvements in post-surgical outcomes that are involved in controlling glucose 
metabolism.71 The protocol for RYGB on the exact length of each limb created after the 
surgery is not standardized, therefore it is difficult to amass a large number of data with 
controlled surgical procedures.  
It should also be noted that the understanding of PYY as the humoral factor that 
directly affects the pancreatic function and insulin and glucagon secretion is a rather 
recent appreciation. Although the study designs were extensive and the results very 
compelling, the efforts and studies on PYY on islet function is limited to a small number 
of research groups. Historically, GLP-1 received high attention and was studied 
extensively. Given that the study of PYY has been done recently, more extensive studies 
to validate the finding in different population is still needed.  
The ‘gut signature’ for T2DM still remains elusive due to several obstacles that is 
common in any emerging field. First, the nature of gut microbiota is easily disrupted and 
affected by many factors outside of metabolic or disease states.  Several discrepancies in 
changes in gut microbiota profiles before and after RYGB surgery were noted in studies 
with Chinese and Scandinavian cohorts.64 This discrepancies may have resulted from 
different diets that patients are exposed to based on their lifestyles as well as cultural 
backgrounds. Second, many studies are reporting results in inconsistent manners without 
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any clear guideline, making it very difficult for information to be consolidated in a 
meaningful way. Thirdly, different species of microbes making up the microbiota have 
symbiotic or antagonistic relationships that may confound the relationship between the 
presence of a specific microbe alone and the phenotype the host exhibits. Although 
several overall trends were observed, this discrepancy makes it difficult to have a 
concrete understanding of exact mechanisms of how the disturbances in gut microbiota 
from gastric bypass surgery leads to improved glucose metabolism and tolerance.  
It should be noted, that the increase in GLP-1, total bile acid levels and gut 
microbiota alteration are not mutually exclusive factors that explain the rapid 
improvement in glucose metabolism post operatively, but rather, are interconnected, 
reciprocally influencing each other. GLP-1 is released from ileal L-cells by secondary 
bile acids through a GPBAR-1 mediated mechanism.59 Effect of gut microbiota to the 
bile acid metabolism and the antimicrobial effect of bile acid onto the intestinal bacteria 
were mentioned above. Future studies in uncovering the mechanisms involved in RYGB 
and T2DM control should put their study design and data in context to over-
encompassing relationships of different physiologic processes that occur after the 
surgery.  
Regardless of the consensus mechanisms involved in RYGB surgery’s beneficial 
effects, studying the physiological mechanism on how the surgical procedure leads to 
T2DM remission independent of weight loss identified new and potential pharmacologic 
therapies that can improve T2DM disease state without the invasive and high-risk 
procedure. GLP-1 receptor agonists and DPP-4 inhibitors are current classes of second-
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line, hypoglycemic medications used to treat T2DM patients and are still of heavily 
studied as the target for therapy.35 In more recent times, PYY has been suggested for 
potential target for T2DM therapy. The importance of understanding the gut microbiota 
composition change from that of T2DM patients before and after RYGB lies in probiotics 
as potential therapy for T2DM.  However, due to challenges in data consolidation and 
inconsistent reporting, along with difficulties in controlling for subjects’ lifestyle and 
diet, creating a standard mix of probiotics for T2DM has been a challenge and a room for 





 Roux-en-Y gastric bypass surgery is proven to be the “gold standard” of bariatric 
surgery currently. RYGB surgery results in swift diabetes remission, defined by 
controlled blood glucose regulation without medication, before any significant weight 
loss.  
 The beneficial anti-diabetic effects of RYGB cannot be solely accounted for the 
drastic weight loss the surgery results. Although the exact mechanism of how RYGB 
elicits immediate T2DM remission still remains largely elusive, it is a heavily studied 
topic. The anti-diabetic benefits are thought to involve improved GLP-1 secretion and 
pancreatic islet morphology and functional recovery from increased PYY secretion. 
Additionally, the increase in total bile acid and alterations in gut microbiota may result in 
changes in the metabolic and hormonal profile of a patient. These changes in metabolic 
and hormonal profile, bile acid metabolism, and gut microbiota composition are 
ultimately resulting from the intestinal anatomic alteration.  
 Although there is yet to be a consensus in the exact mechanism of the swift 
T2DM remission from RYGB surgeries, results from different studies pursuing the 
mechanism have led to many potential T2DM therapeutic targets. GLP-1 agonist and 
DPP-4 inhibitors are current therapeutic hypoglycemic agents. PYY poses a high 
potential to be an anti-diabetic therapeutic target that will promote β-cell function and 
morphology to even already damaged pancreatic islets. Use of probiotics for oral T2DM 
medication holds a high interest in the field for it may affect the bile acid metabolism and 
other overall energy expenditure, but the lack of consistency in data reporting poses 
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challenges to elucidate the exact combination of microbes that can be translated into 
consumable product.  
 Roux-en-Y gastric bypass deems to be a safe, effective therapeutic option for 
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